Therapy of Chronic Cold Agglutinin Disease With Eculizumab
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy and safety of eculizumab in symptomatic or transfusion-dependent
patients with untreated or refractory hemolytic cold agglutinin disease(CAD)
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Essen
Collaborator:
Alexion Pharmaceuticals
Treatments:
Agglutinins Cold agglutinins Complement System Proteins Eculizumab